Eagle Pharmaceuticals Stock Today

EGRX Stock  USD 4.07  0.12  3.04%   


0 of 100

Very Weak

Odds Of Distress

Less than 1

Very Small
Eagle Pharmaceuticals is trading at 4.07 as of the 21st of June 2024; that is 3.04 percent increase since the beginning of the trading day. The stock's open price was 3.95. Eagle Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Eagle Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of July 2022 and ending today, the 21st of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of February 2014
Health Care
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. Eagle Pharmaceuticals, Inc. The company has 12.96 M outstanding shares of which 1.08 M shares are currently shorted by private and institutional investors with about 8.64 trading days to cover. More on Eagle Pharmaceuticals

Moving against Eagle Stock

  0.6LLY Eli LillyPairCorr
  0.58DYAI Dyadic InternationalPairCorr
  0.44MRK Merck Company Financial Report 6th of August 2024 PairCorr
  0.34PFE Pfizer Inc Financial Report 6th of August 2024 PairCorr
  0.31VALN Valneva SE ADR Earnings Call This WeekPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Eagle Stock Highlights

ESG Sustainability
CEOScott Tarriff
Thematic Ideas
(View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Pharmaceutical Products, Cancer Fighters, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.550.7
Significantly Down
Slightly volatile
Total Current Liabilities134.1 M127.8 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total74.3 M70.7 M
Sufficiently Up
Slightly volatile
Total Assets490.4 M467.1 M
Sufficiently Up
Slightly volatile
Total Current Assets137 M217.1 M
Way Down
Slightly volatile
Eagle Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eagle Pharmaceuticals' financial leverage. It provides some insight into what part of Eagle Pharmaceuticals' total assets is financed by creditors.
Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Note, when we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

Eagle Pharmaceuticals (EGRX) is traded on NASDAQ Exchange in USA. It is located in 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677 and employs 134 people. Eagle Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53 M. Eagle Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.96 M outstanding shares of which 1.08 M shares are currently shorted by private and institutional investors with about 8.64 trading days to cover. Eagle Pharmaceuticals currently holds about 36.56 M in cash with 50.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.75.
Check Eagle Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The majority of Eagle Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eagle Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eagle Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eagle Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Eagle Ownership Details

Eagle Stock Institutional Holders

InstituionRecorded OnShares
Marshall Wace Asset Management Ltd2024-03-31
257.5 K
Two Sigma Advisers, Llc2024-03-31
236.3 K
Geode Capital Management, Llc2024-03-31
231.6 K
D. E. Shaw & Co Lp2024-03-31
219.8 K
State Street Corporation2024-03-31
213.7 K
Los Angeles Capital Management Llc2024-03-31
191.7 K
Assenagon Asset Management Sa2024-03-31
185.3 K
Goldman Sachs Group Inc2024-03-31
177.8 K
Dimensional Fund Advisors, Inc.2024-03-31
171.1 K
Nantahala Capital Management, Llc2024-03-31
1.3 M
Aigh Capital Management, Llc2024-03-31
1.2 M
View Eagle Pharmaceuticals Diagnostics

Eagle Pharmaceuticals Historical Income Statement

At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024. View More Fundamentals

Eagle Stock Against Markets

Eagle Pharmaceuticals Corporate Management

Additional Tools for Eagle Stock Analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.